Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.40 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.38 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.38 |
| ▸ | ITGAL | P20701 | 1/20 | 0.38 |
| ▸ | OXTR | P30559 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | CRHBP | P24387 | 2/20 | 0.33 |
| ▸ | CRHR2 | Q13324 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.33 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12401228 | 0.90 | SMN1; SMN2 (0.37) | CD274OXTRSMN1; SMN2 | |
| SCHEMBL20929568 | 0.84 | CD274 (0.51) | CD274 | |
| SCHEMBL4689086 | 0.84 | KDM4E (0.42) | OXTRMAPTKDM4E | |
| SCHEMBL19186630 | 0.75 | ACHE (0.33) | CD274OXTRMTNR1A | |
| SCHEMBL27382541 | 0.73 | ITGB2 (0.53) | ITGB2ICAM1ITGALLMNAMAPT | |
| SCHEMBL11768224 | 0.73 | PNMT (0.39) | — | |
| SCHEMBL265187 | 0.70 | KDM4E (0.49) | KDM4E | |
| SCHEMBL30422918 | 0.70 | KDM4E (0.49) | KDM4E | |
| Bromide SCHEMBL11772850 | 0.70 | PNMT (0.37) | — | |
| Hydrochloric Acid SCHEMBL915241 | 0.69 | KDM4E (0.47) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2528922-B1 | POLYHETEROCYCLIC COMPOUNDS AS HCV INHIBITORS | AB PHARMA LTD (CN) | 2017-08-02 | — | — | EP | disclosed |
| US-8815796-B2 | Polyheterocyclic compounds highly potent as HCV inhibitors | AB Pharma Ltd. (CN) | 2014-08-26 | — | — | US | disclosed |
| US-8815796-B2 | Polyheterocyclic compounds highly potent as HCV inhibitors | AB Pharma Ltd. (CN) | 2014-08-26 | — | — | US | disclosed |
| US-8653025-B2 | Polyheterocyclic compounds highly potent as HCV inhibitors | AB Pharma Ltd. (CN) | 2014-02-18 | — | — | US | disclosed |
| US-8653025-B2 | Polyheterocyclic compounds highly potent as HCV inhibitors | AB Pharma Ltd. (CN) | 2014-02-18 | — | — | US | disclosed |
| WO-2011091757-A1 | POLYHETEROCYCLIC COMPOUNDS HIGHLY POTENT AS HCV INHIBITORS | AB Pharma Ltd. (CN) | 2011-08-04 | — | — | WO | disclosed |
| US-20110183895-A1 | POLYHETEROCYCLIC COMPOUNDS HIGHLY POTENT AS HCV INHIBITORS | AB Pharma Ltd. (CN) | 2011-07-28 | — | — | US | disclosed |
| US-20110183895-A1 | POLYHETEROCYCLIC COMPOUNDS HIGHLY POTENT AS HCV INHIBITORS | AB Pharma Ltd. (CN) | 2011-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110183895-A1 | POLYHETEROCYCLIC COMPOUNDS HIGHLY POTENT AS HCV INHIBITORS | HAVCR2, ZC3HAV1, EIF2AK2 | CD274 2852/4885ITGB2 2702/4885ICAM1 2373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.